Evidence Explorer · MS-N303 · Vitamins · Supportive care · Appraised 11 November 2026
Small cisplatin trials suggested neuroprotection, but a larger double-blind phase III trial across neurotoxic chemotherapies found no meaningful prevention benefit.
Evidence at a glance
- Evidence label: Conflicting evidence; larger phase III trial negative
- Benefit: No significant reduction in neuropathy in the most rigorous broad phase III trial; some smaller cisplatin-specific trials were positive.
- Certainty: Moderate that vitamin E is not a proven general preventive strategy; drug-specific effects remain uncertain because trials are small and heterogeneous.
- Risk: High-dose vitamin E can increase bleeding risk and may interact with anticoagulants, antiplatelet drugs and some cancer treatments.
- Goal: Prevention of chemotherapy neuropathy; not cancer control.
What was studied
Phase III trial: 207 patients receiving neurotoxic chemotherapy were randomized double-blind to vitamin E 400 mg twice daily or placebo. The trial reported no significant benefit for neuropathy incidence, time to onset or chemotherapy dose reductions.
Contradictory evidence: Smaller cisplatin trials using 600 mg/day reported fewer neurologic abnormalities, whereas other chemotherapy-specific trials were null. Meta-analyses have reached different conclusions depending on included drugs and studies.
Identifiers: Primary phase III PMID 20936417, PMCID PMC3329941, NCT00363129.
What this evidence cannot establish
A signal confined to small cisplatin studies does not justify treating vitamin E as effective across taxanes, oxaliplatin and other neurotoxic agents.
These studies do not show improved survival or tumor response, and supplementation should not replace dose modification or guideline-based neuropathy care.
Safety and practical context
Large vitamin E doses can increase bleeding risk, particularly with anticoagulant or antiplatelet medicines. The NIH fact sheet also notes possible interactions with chemotherapy or radiotherapy that should be discussed with the treating team.
The research dose was far above usual dietary intake and is not a self-care recommendation.
Questions for the care team
- Does the evidence match my specific chemotherapy agent?
- Am I taking anticoagulants, antiplatelet drugs or other supplements that raise bleeding risk?
- What guideline-supported neuropathy plan is already in place?
Sources and identifiers
- Randomized phase III trial (PMID 20936417)
- Full text (PMCID PMC3329941)
- ClinicalTrials.gov NCT00363129
- Smaller cisplatin trial (PMID 20194916)
- NIH ODS: Vitamin E fact sheet
- ASCO CIPN guideline update (PMID 32663120)
Funding and conflicts: The phase III trial reported U.S. National Institutes of Health/NCI support.
Source access: Original reports, abstracts/full text where available, registries and authoritative safety sources checked 11 November 2026. The phase III full text and supporting primary abstracts were appraised.
This educational evidence record is not a personal treatment recommendation. Symptom or toxicity findings do not establish tumor response, delayed recurrence or longer survival; laboratory and animal findings are not proof of clinical benefit.
